FDA Grants Priority Review to Roche’s Giredestrant

Roche has moved a step closer to bringing a potential new treatment option to patients with early-stage breast cancer after the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application (NDA) for giredestrant under Priority Review. The investigational oral therapy is being evaluated as an adjuvant treatment for adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage I, II, and III breast cancer.

The FDA is expected to issue a decision on the application by November 30, 2026. If approved, giredestrant could become a significant advancement in endocrine therapy for one of the most common forms of breast cancer.

The regulatory submission is supported by results from Roche’s pivotal Phase III lidERA Breast Cancer trial, which demonstrated that giredestrant significantly reduced the risk of invasive disease recurrence or death compared with standard-of-care endocrine therapy. According to the study, patients receiving giredestrant experienced a 30% reduction in the risk of invasive disease recurrence or death, marking a potentially important improvement in outcomes for people with early-stage ER-positive breast cancer.

Three-year data from the study showed that 92.4% of patients treated with giredestrant remained alive and free of invasive disease, compared with 89.6% of patients receiving current standard endocrine therapies. Researchers reported that the benefit was observed consistently across all clinically relevant patient subgroups, suggesting broad applicability across the early-stage ER-positive breast cancer population.

Although overall survival data remain immature, investigators noted a positive trend favoring giredestrant. Continued follow-up is planned to further assess long-term survival outcomes as the study progresses.

Giredestrant belongs to a class of medicines known as selective oestrogen receptor degraders (SERDs), which are designed to block and degrade the oestrogen receptor, a key driver of tumour growth in many breast cancers. ER-positive disease accounts for approximately 70% of all breast cancer diagnoses, making it the most common subtype worldwide.

Despite advances in treatment, disease recurrence remains a major concern. Up to one-third of patients with early-stage ER-positive breast cancer eventually experience recurrence during or after adjuvant endocrine therapy. In addition, treatment-related side effects often lead some patients to discontinue therapy prematurely, increasing the risk of disease progression and mortality.

Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, described giredestrant as the first major endocrine therapy advancement for early-stage ER-positive breast cancer in decades. He said the FDA’s acceptance of the application brings the company closer to establishing a potential new standard of care for patients in whom the possibility of cure is highest.

The FDA’s decision to grant Priority Review highlights the agency’s recognition of the therapy’s potential clinical importance. Priority Review is reserved for medicines that could provide significant improvements in the treatment, diagnosis, or prevention of serious diseases.

The latest milestone also adds momentum to Roche’s broader giredestrant development program. Earlier this year, the FDA accepted a separate NDA for giredestrant in combination with everolimus for patients with ESR1-mutated, ER-positive advanced breast cancer. A regulatory decision in that indication is expected in December 2026.

Additional analyses from the giredestrant clinical program were recently presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, further supporting the therapy’s potential across both early-stage and advanced breast cancer settings.

With approximately 2.3 million new breast cancer cases diagnosed globally each year, the outcome of the FDA review could have significant implications for patients and clinicians seeking more effective and better-tolerated treatment options to reduce the risk of recurrence and improve long-term outcomes.